Jun 22, 2020
BioInvent and Transgene's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models
Jun 04, 2020
Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses
May 29, 2020
Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting
May 13, 2020
Oncolytics Biotech® to Present at the RBC Global Healthcare Conference
Apr 28, 2020
BioEclipse Receives FDA Clearance of Investigational New Drug Application for CRX100
Apr 22, 2020
Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology
Apr 17, 2020
Oncolytics Biotech® Updates Clinical Development and Operations Activities During the COVID-19 Pandemic
Apr 14, 2020
Applied BioMath Announces Collaboration with OncoMyx Therapeutics for Systems Pharmacology Modeling in Immuno-Oncology
Apr 02, 2020
Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer
Mar 03, 2020
BioInvent and Transgene to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
Feb 20, 2020
Global Markets for Cell Therapies & Oncolytic Virus, Forecast to 2026 - Covering Melanoma, Breast, Ovarian & Prostate Cancer Applications
Feb 10, 2020
Skysong Innovations Completes Licensing Agreement with ASU Spinout OncoMyx Therapeutics
Feb 06, 2020
Valo Therapeutics Announces New Funding for Immuno-Oncology Trials
Jan 22, 2020
Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer
Jan 21, 2020
Some U.S. Airports Begin Checking Passengers for a Deadly New Chinese Virus
Jan 13, 2020
Codagenix Raises $20 Million in Series B Funding for Continued Development of RSV, Influenza and Oncolytic Virus Products
Jan 13, 2020
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma
Jan 13, 2020
DNAtrix Appoints Jeff Knapp as Chief Executive Officer and to Board of Directors
Jan 09, 2020
Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma
Jan 08, 2020
Candel Therapeutics Acquires Next-Generation Herpes Drug Development Platform and Manufacturing Expertise